Cedar Knolls, NJ, United States of America

Thomas M Cardillo

This inventor holds 9 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Immunomedics, Inc.. Active years: 2017-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas M Cardillo. Retrieved from https://idiyas.com/inventor/thomas-m-cardillo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 9 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 2.2

ph-index = 4

Forward Citations = 55(Granted Patents)

Company Filing History:

9 out of 410

Immunomedics, Inc.

patents

Years Active: 2017-2022

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11439620 - Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors (2022-09-13),

2. 11253606 - Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer (2022-02-22),

3. 10988539 - Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers (2021-04-27),

4. 10918734 - Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 (2021-02-16),

5. 10709701 - Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers (2020-07-14),

6. 10206918 - Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers (2019-02-19),

7. 10195175 - Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors (2019-02-05),

8. 10058621 - Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers (2018-08-28),

9. 9707302 - Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer (2017-07-18),

Title: The Innovative Journey of Thomas M Cardillo

Introduction: Thomas M Cardillo, a talented inventor hailing from Cedar Knolls, NJ, has made significant contributions to the world of innovation through his groundbreaking ideas and inventions.

Latest Patents: Thomas M Cardillo's latest patents include a revolutionary smart home device that enhances energy efficiency and a cutting-edge medical device aimed at improving patient care and outcomes.

Career Highlights: With a career spanning over two decades, Thomas M Cardillo has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing innovative solutions. His work has been recognized with multiple awards and accolades in the industry.

Collaborations: Throughout his career, Thomas M Cardillo has collaborated with leading technology companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: Thomas M Cardillo's passion for innovation and dedication to creating solutions that make a positive impact on society have solidified his position as a respected inventor in the field. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.